ALK and lung adenocarcinoma: However, its role as a neoadjuvant therapy remains under investigation.<h4>Case presentation</h4>We report a 57-year-old never-smoking woman diagnosed with stage IIIB (cT4N2M0) ALK-rearranged lung adenocarcinoma.